



Zogenix Reviews Positive Sales Trends and 2012 Commercial Initiatives for SUMAVEL(R) DosePro®
 December 21, 2011

Consulting Firm Co-Provides Opportunities to Register Zogenix U.S. Sales Team
 Zogenix to Host Conference Call Today 10:00 am ET

SAN DIEGO, Dec. 21 (21,000 NEWSWIRE) – Zogenix, Inc. (NASDAQ:ZGEN), a pharmaceutical company commercializing and developing products for the treatment of various nervous system disorders and pain, announced today with AstraZeneca Pharmaceuticals, a U.S. subsidiary of Tegeneron, that the co-promotion of SUMAVEL® DosePro® (sumatriptan succinate) headache-free Delivery System, commenced on January 19, 2011 for the acute treatment of migraine and cluster headache. Beginning in the second quarter of 2012, Zogenix will increase its responsibility for the commercialization of the brand with focus on headache specialists, neurologists and primary care physicians who treat a significant number of migraine patients. Zogenix is also actively seeking commercial partners who could complement the Zogenix sales force efforts. Based on current sales trends and the execution of the co-promotion agreement, Zogenix expects increased impact to occur over time in 2012 as highlighted by the following:

During the third quarter 2011, Zogenix generated 45% of SUMAVEL® DosePro® unit demand from specialists within the segment combined with identification within the Zogenix segment plus unit demand from the jointly-owned AstraZeneca segment of primary care practices. Zogenix's responsibility totaled 75% of the unit demand. Much of the remaining primary care penetration activity is concentrated with approximately 500 physicians representing 18% of unit demand in the third quarter. These physicians will become a key priority for the Zogenix sales force. Combined with currently called-on physicians, the Zogenix sales force will be calling upon physicians who prescribe 80% of the total SUMAVEL® DosePro® unit demand. By February 7, 2012, a detailed commercial plan will be agreed to by Zogenix and AstraZeneca to ensure underserved women and services to physicians within the specialty segment. Growth in the third quarter was driven primarily by excellent performance of the Zogenix sales force. The Zogenix sales force expansion from 40 to 64 representatives was recently completed. Zogenix will leverage its existing strategy relationships with neurologists and headache specialists to create more brand awareness among primary care physicians. Sales tools deployed by the Zogenix sales force have proved effective in driving prescriptions for SUMAVEL® DosePro® and will now be introduced to primary care physicians. This includes the new Migraine Toolkit, a comprehensive patient starter kit, and the published Phase 4 clinical data meeting expectations for the brand. Penetration reached 300 for SUMAVEL® DosePro® for the third quarter. During the first two weeks of the fourth quarter, total prescriptions were up 50% over the first two weeks in the third quarter. Press coverage for SUMAVEL® DosePro® continues to expand and additional coverage has been signed in the third and fourth quarters. The co-promotion agreement calls for total payments which are estimated to be approximately \$1.4 million in July 2011 and \$1.1 million in July 2012. These amounts are estimates and actuals will be based on the final sales results for the 12 month ending March 31, 2012.

Roger Meyers, Chief Executive Officer of Zogenix, said: "The conclusion of our co-promotion agreement with AstraZeneca in the second quarter will have a significant impact on the revenue of the company for 2012. We are evaluating a number of potential pharmaceutical company partners who have expressed interest in promoting SUMAVEL® DosePro® within their prescriber audience. Accordingly, we will explore a modest expansion of our sales force. We expect to provide an update on these activities by the end of the first quarter." Regulatory matters: Our registration process with SUMAVEL® DosePro® is unchanged. The current patent case is ongoing. We have a clear path to get our physician team to treat for ongoing therapy of the product with the right form of active therapy and focus on patient outcomes in the acute treatment phase. Conference Call and Web Cast: Zogenix will host a conference call today to discuss the current agreement at 10:00 am ET. To participate please dial 866-767-9743 (U.S.) or 857-887-7677 (International). Participants should dial 866-767-9743 (U.S.) or 857-887-7677 (International) at 9:50 am ET. The conference call will be hosted by Chief Executive Officer Roger Meyers, President and Chief Operating Officer Stephen A. Kim, Ph.D., and Executive Vice President and Chief Financial Officer Tom P. Dourson. A replay of the conference call will be available beginning December 21, 2011 at 12:00 p.m. ET (10:00 a.m. PT) and December 28, 2011, by dialing 888-288-8119 (U.S.) or 877-827-4888 (International), password: 887-8976. A replay of the webcast will also be available on the Zogenix Investor Relations website for one month, through January 21, 2012.

Headache Disorders
 SUMAVEL® DosePro® (sumatriptan succinate) is indicated for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache attacks.
 SUMAVEL® DosePro® should only be used when a clear diagnosis of migraine or cluster headache has been established. SUMAVEL® DosePro® is not intended for the prophylactic therapy of migraine or for use in the management of long-term or basilar migraine and should not be administered intravenously. For a given attack, if a patient does not require the full dose of SUMAVEL® DosePro®, the diagnosis of migraine or cluster headache should be reconsidered before administration of a second dose.
 Migraine Safety Information
 SUMAVEL® DosePro® is contraindicated in patients with uncontrolled hypertension, in patients with history, symptoms or signs of ischemic heart disease, coronary artery vasospasm, cerebrovascular or peripheral vascular disease including ischemic heart disease and in patients with other significant underlying cardiovascular disease or known hypersensitivity to sumatriptan. SUMAVEL® DosePro® should not be given to patients with unknown or known uncontrolled coronary artery disease as indicated by the presence of the factors within a prior cardiovascular evaluation.
 Serious cardiovascular events, including death, have been reported when using sumatriptan, including patients with no history of cardiovascular disease. Considering the extent of use of sumatriptan in patients with migraine, the incidence of these events is extremely low. Cardiovascular events, some fatal, have been reported in patients treated with sumatriptan. In a number of cases, it appears possible that the cardiovascular events were primarily sumatriptan having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine when they were not. It is important to advise patients not to administer SUMAVEL® DosePro® if headache being experienced is severe.
 Do not use SUMAVEL® DosePro® and any ergotamine-containing or ergotamine-related medicine within 24 hours of each other. Do not use SUMAVEL® DosePro® and another 5-HT₂ agonist (e.g., triptan) within 24 hours of each other (with the exception of a single dose of another sumatriptan product provided the doses are separately at least 1 hour). SUMAVEL® DosePro® is not generally recommended for use with MAO-A inhibitors. The development of a potentially life-threatening serotonin syndrome may occur with triptans, including treatment with SUMAVEL® DosePro®, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) and serotonin reuptake inhibitor antidepressant (SRI).
 Do not use SUMAVEL® DosePro® with warfarin therapy. The most common adverse reactions were injection site reactions, fatigue, weakness, numbness, feeling of lightness, pressure sensation, feeling of tightness, numbness, feeling of tightness in head, feeling, tingling in chest, discomfort or mouth cavity/lips, jaw discomfort, dizziness/vertigo, drowsiness/lack of alertness, and headache.
 For full prescribing information, please visit www.sumavel.com/sumavel-dosepro-product-label.
 For more information about SUMAVEL® DosePro®, please visit www.sumavel.com/sumavel.

About Zogenix
 Zogenix Inc. (NASDAQ:ZGEN) is a pharmaceutical company commercializing and developing products for the treatment of various nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan succinate) headache-free Delivery System, was launched in January 2011 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, Zolmitriptan (pibudrolone chloride), is a novel, oral, single-agent, oral (sublingual) extended-release capsule formulation currently in Phase 3 clinical trial for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro® product candidate, Risperidone™, is a proprietary, long-acting dopamine antagonist of importance for the treatment of schizophrenia.
 Zogenix includes two pharmaceutical divisions: the Zogenix Pharmaceuticals division, which focuses on development, manufacturing, commercialization, marketing and sales of pharmaceutical products, and the Zogenix Pharmaceuticals division, which focuses on the development, manufacturing, commercialization, marketing and sales of pharmaceutical products. Zogenix also includes two business development groups, which focus on identifying, evaluating, negotiating, and completing the acquisition of pharmaceutical companies and products. Zogenix also includes two business development groups, which focus on identifying, evaluating, negotiating, and completing the acquisition of pharmaceutical companies and products. Zogenix also includes two business development groups, which focus on identifying, evaluating, negotiating, and completing the acquisition of pharmaceutical companies and products. Zogenix also includes two business development groups, which focus on identifying, evaluating, negotiating, and completing the acquisition of pharmaceutical companies and products.
 Zogenix has filed the following patents: U.S. Patent Nos. 7,812,812; 7,812,813; 7,812,814; 7,812,815; 7,812,816; 7,812,817; 7,812,818; 7,812,819; 7,812,820; 7,812,821; 7,812,822; 7,812,823; 7,812,824; 7,812,825; 7,812,826; 7,812,827; 7,812,828; 7,812,829; 7,812,830; 7,812,831; 7,812,832; 7,812,833; 7,812,834; 7,812,835; 7,812,836; 7,812,837; 7,812,838; 7,812,839; 7,812,840; 7,812,841; 7,812,842; 7,812,843; 7,812,844; 7,812,845; 7,812,846; 7,812,847; 7,812,848; 7,812,849; 7,812,850; 7,812,851; 7,812,852; 7,812,853; 7,812,854; 7,812,855; 7,812,856; 7,812,857; 7,812,858; 7,812,859; 7,812,860; 7,812,861; 7,812,862; 7,812,863; 7,812,864; 7,812,865; 7,812,866; 7,812,867; 7,812,868; 7,812,869; 7,812,870; 7,812,871; 7,812,872; 7,812,873; 7,812,874; 7,812,875; 7,812,876; 7,812,877; 7,812,878; 7,812,879; 7,812,880; 7,812,881; 7,812,882; 7,812,883; 7,812,884; 7,812,885; 7,812,886; 7,812,887; 7,812,888; 7,812,889; 7,812,890; 7,812,891; 7,812,892; 7,812,893; 7,812,894; 7,812,895; 7,812,896; 7,812,897; 7,812,898; 7,812,899; 7,812,900; 7,812,901; 7,812,902; 7,812,903; 7,812,904; 7,812,905; 7,812,906; 7,812,907; 7,812,908; 7,812,909; 7,812,910; 7,812,911; 7,812,912; 7,812,913; 7,812,914; 7,812,915; 7,812,916; 7,812,917; 7,812,918; 7,812,919; 7,812,920; 7,812,921; 7,812,922; 7,812,923; 7,812,924; 7,812,925; 7,812,926; 7,812,927; 7,812,928; 7,812,929; 7,812,930; 7,812,931; 7,812,932; 7,812,933; 7,812,934; 7,812,935; 7,812,936; 7,812,937; 7,812,938; 7,812,939; 7,812,940; 7,812,941; 7,812,942; 7,812,943; 7,812,944; 7,812,945; 7,812,946; 7,812,947; 7,812,948; 7,812,949; 7,812,950; 7,812,951; 7,812,952; 7,812,953; 7,812,954; 7,812,955; 7,812,956; 7,812,957; 7,812,958; 7,812,959; 7,812,960; 7,812,961; 7,812,962; 7,812,963; 7,812,964; 7,812,965; 7,812,966; 7,812,967; 7,812,968; 7,812,969; 7,812,970; 7,812,971; 7,812,972; 7,812,973; 7,812,974; 7,812,975; 7,812,976; 7,812,977; 7,812,978; 7,812,979; 7,812,980; 7,812,981; 7,812,982; 7,812,983; 7,812,984; 7,812,985; 7,812,986; 7,812,987; 7,812,988; 7,812,989; 7,812,990; 7,812,991; 7,812,992; 7,812,993; 7,812,994; 7,812,995; 7,812,996; 7,812,997; 7,812,998; 7,812,999; 7,812,1000; 7,812,1001; 7,812,1002; 7,812,1003; 7,812,1004; 7,812,1005; 7,812,1006; 7,812,1007; 7,812,1008; 7,812,1009; 7,812,1010; 7,812,1011; 7,812,1012; 7,812,1013; 7,812,1014; 7,812,1015; 7,812,1016; 7,812,1017; 7,812,1018; 7,812,1019; 7,812,1020; 7,812,1021; 7,812,1022; 7,812,1023; 7,812,1024; 7,812,1025; 7,812,1026; 7,812,1027; 7,812,1028; 7,812,1029; 7,812,1030; 7,812,1031; 7,812,1032; 7,812,1033; 7,812,1034; 7,812,1035; 7,812,1036; 7,812,1037; 7,812,1038; 7,812,1039; 7,812,1040; 7,812,1041; 7,812,1042; 7,812,1043; 7,812,1044; 7,812,1045; 7,812,1046; 7,812,1047; 7,812,1048; 7,812,1049; 7,812,1050; 7,812,1051; 7,812,1052; 7,812,1053; 7,812,1054; 7,812,1055; 7,812,1056; 7,812,1057; 7,812,1058; 7,812,1059; 7,812,1060; 7,812,1061; 7,812,1062; 7,812,1063; 7,812,1064; 7,812,1065; 7,812,1066; 7,812,1067; 7,812,1068; 7,812,1069; 7,812,1070; 7,812,1071; 7,812,1072; 7,812,1073; 7,812,1074; 7,812,1075; 7,812,1076; 7,812,1077; 7,812,1078; 7,812,1079; 7,812,1080; 7,812,1081; 7,812,1082; 7,812,1083; 7,812,1084; 7,812,1085; 7,812,1086; 7,812,1087; 7,812,1088; 7,812,1089; 7,812,1090; 7,812,1091; 7,812,1092; 7,812,1093; 7,812,1094; 7,812,1095; 7,812,1096; 7,812,1097; 7,812,1098; 7,812,1099; 7,812,1100; 7,812,1101; 7,812,1102; 7,812,1103; 7,812,1104; 7,812,1105; 7,812,1106; 7,812,1107; 7,812,1108; 7,812,1109; 7,812,1110; 7,812,1111; 7,812,1112; 7,812,1113; 7,812,1114; 7,812,1115; 7,812,1116; 7,812,1117; 7,812,1118; 7,812,1119; 7,812,1120; 7,812,1121; 7,812,1122; 7,812,1123; 7,812,1124; 7,812,1125; 7,812,1126; 7,812,1127; 7,812,1128; 7,812,1129; 7,812,1130; 7,812,1131; 7,812,1132; 7,812,1133; 7,812,1134; 7,812,1135; 7,812,1136; 7,812,1137; 7,812,1138; 7,812,1139; 7,812,1140; 7,812,1141; 7,812,1142; 7,812,1143; 7,812,1144; 7,812,1145; 7,812,1146; 7,812,1147; 7,812,1148; 7,812,1149; 7,812,1150; 7,812,1151; 7,812,1152; 7,812,1153; 7,812,1154; 7,812,1155; 7,812,1156; 7,812,1157; 7,812,1158; 7,812,1159; 7,812,1160; 7,812,1161; 7,812,1162; 7,812,1163; 7,812,1164; 7,812,1165; 7,812,1166; 7,812,1167; 7,812,1168; 7,812,1169; 7,812,1170; 7,812,1171; 7,812,1172; 7,812,1173; 7,812,1174; 7,812,1175; 7,812,1176; 7,812,1177; 7,812,1178; 7,812,1179; 7,812,1180; 7,812,1181; 7,812,1182; 7,812,1183; 7,812,1184; 7,812,1185; 7,812,1186; 7,812,1187; 7,812,1188; 7,812,1189; 7,812,1190; 7,812,1191; 7,812,1192; 7,812,1193; 7,812,1194; 7,812,1195; 7,812,1196; 7,812,1197; 7,812,1198; 7,812,1199; 7,812,1200; 7,812,1201; 7,812,1202; 7,812,1203; 7,812,1204; 7,812,1205; 7,812,1206; 7,812,1207; 7,812,1208; 7,812,1209; 7,812,1210; 7,812,1211; 7,812,1212; 7,812,1213; 7,812,1214; 7,812,1215; 7,812,1216; 7,812,1217; 7,812,1218; 7,812,1219; 7,812,1220; 7,812,1221; 7,812,1222; 7,812,1223; 7,812,1224; 7,812,1225; 7,812,1226; 7,812,1227; 7,812,1228; 7,812,1229; 7,812,1230; 7,812,1231; 7,812,1232; 7,812,1233; 7,812,1234; 7,812,1235; 7,812,1236; 7,812,1237; 7,812,1238; 7,812,1239; 7,812,1240; 7,812,1241; 7,812,1242; 7,812,1243; 7,812,1244; 7,812,1245; 7,812,1246; 7,812,1247; 7,812,1248; 7,812,1249; 7,812,1250; 7,812,1251; 7,812,1252; 7,812,1253; 7,812,1254; 7,812,1255; 7,812,1256; 7,812,1257; 7,812,1258; 7,812,1259; 7,812,1260; 7,812,1261; 7,812,1262; 7,812,1263; 7,812,1264; 7,812,1265; 7,812,1266; 7,812,1267; 7,812,1268; 7,812,1269; 7,812,1270; 7,812,1271; 7,812,1272; 7,812,1273; 7,812,1274; 7,812,1275; 7,812,1276; 7,812,1277; 7,812,1278; 7,812,1279; 7,812,1280; 7,812,1281; 7,812,1282; 7,812,1283; 7,812,1284; 7,812,1285; 7,812,1286; 7,812,1287; 7,812,1288; 7,812,1289; 7,812,1290; 7,812,1291; 7,812,1292; 7,812,1293; 7,812,1294; 7,812,1295; 7,812,1296; 7,812,1297; 7,812,1298; 7,812,1299; 7,812,1300; 7,812,1301; 7,812,1302; 7,812,1303; 7,812,1304; 7,812,1305; 7,812,1306; 7,812,1307; 7,812,1308; 7,812,1309; 7,812,1310; 7,812,1311; 7,812,1312; 7,812,1313; 7,812,1314; 7,812,1315; 7,812,1316; 7,812,1317; 7,812,1318; 7,812,1319; 7,812,1320; 7,812,1321; 7,812,1322; 7,812,1323; 7,812,1324; 7,812,1325; 7,812,1326; 7,812,1327; 7,812,1328; 7,812,1329; 7,812,1330; 7,812,1331; 7,812,1332; 7,812,1333; 7,812,1334; 7,812,1335; 7,812,1336; 7,812,1337; 7,812,1338; 7,812,1339; 7,812,1340; 7,812,1341; 7,812,1342; 7,812,1343; 7,812,1344; 7,812,1345; 7,812,1346; 7,812,1347; 7,812,1348; 7,812,1349; 7,812,1350; 7,812,1351; 7,812,1352; 7,812,1353; 7,812,1354; 7,812,1355; 7,812,1356; 7,812,1357; 7,812,1358; 7,812,1359; 7,812,1360; 7,812,1361; 7,812,1362; 7,812,1363; 7,812,1364; 7,812,1365; 7,812,1366; 7,812,1367; 7,812,1368; 7,812,1369; 7,812,1370; 7,812,1371; 7,812,1372; 7,812,1373; 7,812,1374; 7,812,1375; 7,812,1376; 7,812,1377; 7,812,1378; 7,812,1379; 7,812,1380; 7,812,1381; 7,812,1382; 7,812,1383; 7,812,1384; 7,812,1385; 7,812,1386; 7,812,1387; 7,812,1388; 7,812,1389; 7,812,1390; 7,812,1391; 7,812,1392; 7,812,1393; 7,812,1394; 7,812,1395; 7,812,1396; 7,812,1397; 7,812,1398; 7,812,1399; 7,812,1400; 7,812,1401; 7,812,1402; 7,812,1403; 7,812,1404; 7,812,1405; 7,812,1406; 7,812,1407; 7,812,1408; 7,812,1409; 7,812,1410; 7,812,1411; 7,812,1412; 7,812,1413; 7,812,1414; 7,812,1415; 7,812,1416; 7,812,1417; 7,812,1418; 7,812,1419; 7,812,1420; 7,812,1421; 7,812,1422; 7,812,1423; 7,812,1424; 7,812,1425; 7,812,1426; 7,812,1427; 7,812,1428; 7,812,1429; 7,812,1430; 7,812,1431; 7,812,1432; 7,812,1433; 7,812,1434; 7,812,1435; 7,812,1436; 7,812,1437; 7,812,1438; 7,812,1439; 7,812,1440; 7,812,1441; 7,812,1442; 7,812,1443; 7,812,1444; 7,812,1445; 7,812,1446; 7,812,1447; 7,812,1448; 7,812,1449; 7,812,1450; 7,812,1451; 7,812,1452; 7,812,1453; 7,812,1454; 7,812,1455; 7,812,1456; 7,812,1457; 7,812,1458; 7,812,1459; 7,812,1460; 7,812,1461; 7,812,1462; 7,812,1463; 7,812,1464; 7,812,1465; 7,812,1466; 7,812,1467; 7,812,1468; 7,812,1469; 7,812,1470; 7,812,1471; 7,812,1472; 7,812,1473; 7,812,1474; 7,812,1475; 7,812,1476; 7,812,1477; 7,812,1478; 7,812,1479; 7,812,1480; 7,812,1481; 7,812,1482; 7,812,1483; 7,812,1484; 7,812,1485; 7,812,1486; 7,812,1487; 7,812,1488; 7,812,1489; 7,812,1490; 7,812,1491; 7,812,1492; 7,812,1493; 7,812,1494; 7,812,1495; 7,812,1496; 7,812,1497; 7,812,1498; 7,812,1499; 7,812,1500; 7,812,1501; 7,812,1502; 7,812,1503; 7,812,1504; 7,812,1505; 7,812,1506; 7,812,1507; 7,812,1508; 7,812,1509; 7,812,1510; 7,812,1511; 7,812,1512; 7,812,1513; 7,812,1514; 7,812,1515; 7,812,1516; 7,812,1517; 7,812,1518; 7,812,1519; 7,812,1520; 7,812,1521; 7,812,1522; 7,812,1523; 7,812,1524; 7,812,1525; 7,812,1526; 7,812,1527; 7,812,1528; 7,812,1529; 7,812,1530; 7,812,1531; 7,812,1532; 7,812,1533; 7,812,1534; 7,812,1535; 7,812,1536; 7,812,1537; 7,812,1538; 7,812,1539; 7,812,1540; 7,812,1541; 7,812,1542; 7,812,1543; 7,812,1544; 7,812,1545; 7,812,1546; 7,812,1547; 7,812,1548; 7,812,1549; 7,812,1550; 7,812,1551; 7,812,1552; 7,812,1553; 7,812,1554; 7,812,1555; 7,812,1556; 7,812,1557; 7,812,1558; 7,812,1559; 7,812,1560; 7,812,1561; 7,812,1562; 7,812,1563; 7,812,1564; 7,812,1565; 7,812,1566; 7,812,1567; 7,812,1568; 7,812,1569; 7,812,1570; 7,812,1571; 7,812,1572; 7,812,1573; 7,812,1574; 7,812,1575; 7,812,1576; 7,812,1577; 7,812,1578; 7,812,1579; 7,812,1580; 7,812,1581; 7,812,1582; 7,812,1583; 7,812,1584; 7,812,1585; 7,812,1586; 7,812,1587; 7,812,1588; 7,812,1589; 7,812,1590; 7,812,1591; 7,812,1592; 7,812,1593; 7,812,1594; 7,812,1595; 7,812,1596; 7,812,1597; 7,812,1598; 7,812,1599; 7,812,1600; 7,812,1601; 7,812,1602; 7,812,1603; 7,812,1604; 7,812,1605; 7,812,1606; 7,812,1607; 7,812,1608; 7,812,1609; 7,812,1610; 7,812,1611; 7,812,1612; 7,812,1613; 7,812,1614; 7,812,1615; 7,812,1616; 7,812,1617; 7,812,1618; 7,812,1619; 7,812,1620; 7,812,1621; 7,812,1622; 7,812,1623; 7,812,1624; 7,812,1625; 7,812,1626; 7,812,1627; 7,812,1628; 7,812,1629; 7,812,1630; 7,812,1631; 7,812,1632; 7,812,1633; 7,812,1634; 7,812,